The University of Liverpool’s spin-out company, Galytx, has signed an exclusive licensing agreement with dermatology biotech Quodria.   Together the companies plan to develop a first-in-class treatment for atopic dermatitis (AD), a form of eczema.  Galytx, launched in June 2024, focuses on the development of galectin-3 targeted therapeutics for the treatment of inflammatory diseases, cancer, and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!